David H. Gutmann, MD, PhD, FAAN  gutmannd@wustl.edu

Profile picture



  • BS, Highest Honors, The University of Michigan1979
  • MS, The University of Michigan1980
  • MD, With Distinction, The University of Michigan Medical School1986
  • PhD, The University of Michigan1984


  • Internship, The Hospital of The University of Pennsylvania1986 - 1987
  • Residency, The Hospital of The University of Pennsylvania1987 - 1990
  • Postdoctoral Fellowship, The University of Michigan Medical Center1990 - 1993

Licensure and Board Certification

  • 1986PA, Medical License
  • 1990MI, Medical License
  • 1992 - PresNeurology Board Certification
  • 1993 - PresMO, Medical License

Honors and Awards

  • Gordon-Timmis Research Fellowship1977
  • Michigan Alumni-Regents Scholarship1977
  • Henry Ford Hospital Research Fellowship1978
  • Campbell Cancer Research Fellowship1980
  • March of Dimes Thomas Francis, Jr. Award1980
  • Campbell Cancer Research Fellowship1981
  • Campbell Cancer Research Fellowship1982
  • Horace H. Rackham PreDoctoral Fellowship1982
  • Campbell Cancer Research Fellowship1983
  • Horace H. Rackham PreDoctoral Fellowship1983
  • NIH Clinical Investigator Development Award (K08), NINDS1992
  • March of Dimes Young Investigator Award, FASEB Summer1993
  • Peter A. Aron National Neurofibromatosis Foundation Award1994
  • Decade of the Brain Plenary Session Speaker, American Academy of Neurology1996
  • American Neurological Association, elected member1997
  • Carolyn Farb Endowed Lecture in Neurofibromatosis1998
  • National Neurofibromatosis Foundation Crystal Award1998
  • Eliason Teaching Award, Department of Neurology1999
  • Fellow, American Neurological Association1999
  • Walker Lecturer in Neurofibromatosis1999
  • Linse Block Neuro-oncology Visiting Professor, Mayo Clinic Foundation2001
  • Donald O. Schnuck Family (Endowed) Chair in Neurology2002
  • National Neurofibromatosis Foundation Center of Excellence Award2002
  • American Society for Clinical Investigation Induction2003
  • Washington University School of Medicine Clinical Teacher of the Year Award2003
  • Manuel R. Gomez Named Visiting Professor2006
  • Award for Excellence in Pediatric Basic/Translational Research, Society for Neuro-Oncology2007
  • Ninth Annual Arthur and Sonia Labatt Brain Tumor Research Centre Lecturer2007
  • Award for Excellence in Pediatric Translational Research, Society for Neuro-Oncology2008
  • Takao Hoshino Lectureship, University of California – San Francisco2008
  • Pfizer Visiting Professor, University of Virginia2010
  • Ranked in top 10% of Barnes-Jewish Hospital Physician Providers (Patient Satisfaction)2010
  • University of Arkansas MD/PhD Student Choice Speaker2010
  • Washington University/Siteman Cancer Center “Rock Doc”2010
  • Children’s Tumor Foundation Frederich Von Recklinghausen (Lifetime Achievement) Award2012
  • 16th Annual Sara Hertafeld Memorial Lectureship2013
  • Susan B. Stine Memorial Lectureship2013
  • Washington University Distinguished Faculty Research Award2013
  • 8th Annual Riley Church Guest Professor, Stanford University2014
  • Oregon Society for Neuroscience Retreat Keynote speaker2015
  • Alexander von Humboldt Research Award2017
  • Berlin Institute of Health Einstein Visiting Fellowship2017 - Pres
  • Elected Fellow, American Academy of Neurology (AAN)2018
  • Abjihit Guha Award and Lecture2019

Recent Publications view all (438)

Publication Co-Authors

  1. Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. Acta Neuropathol Commun. 2019;7(1):20. PMCID:PMC6376799  PMID:30764877 
  2. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019. PMID:30733593 
  3. Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging. Dev Med Child Neurol. 2019. PMID:30659594 
  4. Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation. J Sleep Res. 2019;e12816. PMID:30609083 
  5. KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production. Neoplasia. 2019;21(1):52-60. PMCID:PMC6277251  PMID:30504064 
  6. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. J Neurosci Res. 2019;97(1):45-56. PMID:29704429 
  7. Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes. Bull Math Biol. 2018. PMID:30350013 
  8. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Commun Biol. 2018;1:158. PMCID:PMC6168575  PMID:30302402 
  9. Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes. J Child Neurol. 2018;33(12):762-766. PMID:30009646 
  10. Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1. Neurol Clin Pract. 2018;8(4):283-291. PMCID:PMC6105062  PMID:30140579 
  11. Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1. Neurol Genet. 2018;4(4):e261. PMCID:PMC6066364  PMID:30065955 
  12. Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. PLoS One. 2018;13(5):e0190001. PMCID:PMC5963759  PMID:29787563 
  13. β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. Neuro Oncol. 2018;20(6):858-860. PMCID:PMC5961120  PMID:29596596 
  14. Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth. Genes Dev. 2018;32(7-8):491-496. PMCID:PMC5959233  PMID:29632086 
  15. A Conserved Circadian Function for the Neurofibromatosis 1 Gene. Cell Rep. 2018;22(13):3416-3426. PMCID:PMC5898822  PMID:29590612 
  16. Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. Pediatr Blood Cancer. 2018;65(3). PMID:29049847 
  17. A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1. Neurology. 2018;90(8):377-379. PMID:29367450 
  18. Human stem cell modeling in neurofibromatosis type 1 (NF1). Exp Neurol. 2018;299(Pt B):270-280. PMCID:PMC5630478  PMID:28392281 
  19. Characterization of early communicative behavior in mouse models of neurofibromatosis type 1. Autism Res. 2018;11(1):44-58. PMCID:PMC5773379  PMID:28842941 
  20. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J. 2017;36(24):3650-3665. PMCID:PMC5730846  PMID:29127155 
  21. Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner. Epilepsia. 2017;58(12):2053-2063. PMCID:PMC5716871  PMID:29023667 
  22. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017;171(4):950-965.e28. PMCID:PMC5693358  PMID:29100075 
  23. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol. 2017;59(11):1112-1116. PMID:28845518 
  24. Children with 5'-end NF1 gene mutations are more likely to have glioma. Neurol Genet. 2017;3(5):e192. PMCID:PMC5610042  PMID:28955729 
  25. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol. 2017;37 Suppl 1:S23-S32. PMID:28806346 
  26. Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature. Oncotarget. 2017;8(32):52474-52487. PMCID:PMC5581044  PMID:28881745 
  27. Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. J Natl Cancer Inst. 2017;109(8). PMCID:PMC6057517  PMID:29117388 
  28. Updated nomenclature for human and mouse neurofibromatosis type 1 genes. Neurol Genet. 2017;3(4):e169. PMCID:PMC5530422  PMID:28804759 
  29. CNS Tumors in Neurofibromatosis. J Clin Oncol. 2017;35(21):2378-2385. PMCID:PMC5516481  PMID:28640700 
  30. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Oncotarget. 2017;8(29):47206-47215. PMCID:PMC5564557  PMID:28525381 
  31. KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget. 2017;8(29):47574-47585. PMCID:PMC5564588  PMID:28548933 
  32. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro Oncol. 2017;19(6):808-819. PMCID:PMC5464459  PMID:28039362 
  33. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A. 2017;173(6):1714-1721. PMID:28436162 
  34. MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. J Neurosci. 2017;37(22):5574-5586. PMCID:PMC5452343  PMID:28416596 
  35. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget. 2017;8(20):32977-32989. PMCID:PMC5464843  PMID:28380429 
  36. Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Res. 2017;77(9):2266-2278. PMCID:PMC5741820  PMID:28235764 
  37. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 2017;15(5):e1002605. PMCID:PMC5446120  PMID:28549068 
  38. Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma. Biophys J. 2017;112(8):1535-1538. PMCID:PMC5406378  PMID:28445745 
  39. A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology. 2017;88(16):1584-1589. PMCID:PMC5395076  PMID:28330960 
  40. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer. 2017;123(7):1194-1201. PMID:27875628 
  41. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. PMID:28230061 
  42. A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury. J Biol Chem. 2017;292(4):1240-1250. PMCID:PMC5270470  PMID:27941025 
  43. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med. 2017;214(1):17-25. PMCID:PMC5206494  PMID:27923908 
  44. The management of neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: Challenges, progress, and future prospects. Expert Opinion on Orphan Drugs. 2017;5:623-631. 
  45. Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Front Oncol. 2016;6:259. PMCID:PMC5167692  PMID:28066715 
  46. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016;87(24):2575-2584. PMCID:PMC5207004  PMID:27956565 
  47. Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry. 2016;73(12):1276-1284. PMCID:PMC5298203  PMID:27760236 
  48. Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1. J Child Neurol. 2016;31(14):1540-1545. PMID:27581847 
  49. 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. J Proteomics. 2016;149:77-84. PMCID:PMC4983271  PMID:26883872 
  50. Contextual signaling in cancer. Semin Cell Dev Biol. 2016;58:118-26. PMCID:PMC5028257  PMID:27269372 
  51. Gliosarcomas lack BRAFV600E mutation, but a subset exhibit β-catenin nuclear localization. Neuropathology. 2016;36(5):448-455. PMID:26932501 
  52. Exploring the genetic basis for clinical variation in neurofibromatosis type 1. Expert Rev Neurother. 2016;16(9):999-1001. PMCID:PMC4998178  PMID:27171602 
  53. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. Neurology. 2016;87(7 Suppl 1):S13-20. PMCID:PMC5578358  PMID:27527645 
  54. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016;87(7 Suppl 1):S40-8. PMCID:PMC5578360  PMID:27527649 
  55. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016;87(7 Suppl 1):S21-30. PMCID:PMC5578356  PMID:27527646 
  56. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016;87(7 Suppl 1):S31-9. PMCID:PMC5578359  PMID:27527647 
  57. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016;87(7 Suppl 1):S4-S12. PMCID:PMC5578357  PMID:27527648 
  58. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I. Dis Model Mech. 2016;9(7):759-67. PMCID:PMC4958313  PMID:27482814 
  59. Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. Genes Dev. 2016;30(12):1383-8. PMCID:PMC4926861  PMID:27340174 
  60. Pediatric gliomas as neurodevelopmental disorders. Glia. 2016;64(6):879-95. PMCID:PMC4833573  PMID:26638183 
  61. Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol. 2016;42:53-9. PMCID:PMC4899111  PMID:27018750 
  62. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. Hum Mol Genet. 2016;25(9):1703-13. PMCID:PMC4986327  PMID:26908603 
  63. ABCG1 maintains high-grade glioma survival in vitro and in vivo. Oncotarget. 2016;7(17):23416-24. PMCID:PMC5029636  PMID:26981778 
  64. Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1. Fam Cancer. 2016;15(2):301-8. PMCID:PMC5080205  PMID:26666764 
  65. De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging. Radiol Case Rep. 2016;11(1):33-5. PMCID:PMC4769616  PMID:26973730 
  66. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget. 2016;7(7):7403-14. PMCID:PMC4884927  PMID:26859681 
  67. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016;164(3):550-63. PMCID:PMC4754110  PMID:26824661 
  68. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19(1):20-7. PMCID:PMC4876023  PMID:26713745 
  69. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry. 2015;20(11):1311-21. PMCID:PMC5603719  PMID:25917366 
  70. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia. 2015;17(10):776-88. PMCID:PMC4656811  PMID:26585233 
  71. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clin Cancer Res. 2015;21(18):4201-11. PMCID:PMC4573781  PMID:25925892 
  72. Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I. J Pediatr. 2015;167(3):621-6.e1. PMCID:PMC4792262  PMID:26051969 
  73. Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1. J Pediatr. 2015;167(3):613-20.e1-2. PMCID:PMC4784699  PMID:26028287 
  74. Neurofibromatosis-1 regulation of neural stem cell proliferation and multilineage differentiation operates through distinct RAS effector pathways. Genes Dev. 2015;29(16):1677-82. PMCID:PMC4561477  PMID:26272820 
  75. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet. 2015;24(12):3518-28. PMCID:PMC4553714  PMID:25788518 
  76. Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner. Stem Cells. 2015;33(6):1998-2010. PMCID:PMC4889217  PMID:25788415 
  77. Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative. Fam Cancer. 2015;14(2):317-24. PMID:25523354 
  78. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro Oncol. 2015;17(6):843-53. PMCID:PMC4483119  PMID:25534823 
  79. The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol. 2015;17(5):670-7. PMCID:PMC4482850  PMID:25246427 
  80. Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther. 2015;15(4):415-23. PMID:25652347 
  81. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17(4):596-603.